ACH-3102: Additional Phase II data
Additional data from the 12-week, double-blind, placebo-controlled, U.S. and Canadian Phase II 007 trial in 30 treatment-naïve patients with chronic HCV genotype 1 infection showed that 100% of patients with HCV genotype 1b infection who received 200 (n=4) or 400 (n=4) mg sovaprevir plus ACH-3102 and ribavirin achieved an SVR 12 weeks after the end of treatment. Achillion said SVR rates in patients with HCV genotype 1a infection were "suboptimal" and the company has no plans to pursue the combination for HCV genotype 1a infection. Patients received once-daily 200 or 400 mg sovaprevir plus ACH-3102 given as a 150 mg loading dose followed by 50 mg once daily in combination with ribavirin for 12 weeks. Data were presented at the Asia Pacific Association for the Study of the Liver meeting in Brisbane. Achillion reported interim data from the trial last September (see BioCentury, Oct. 7, 2013).
Mid-year, Achillion plans to start a Phase II trial to evaluate ACH-3102 in combination with its ACH-2684, an HCV NS3/4A protease inhibitor, in patients with HCV genotype 1b infection. Early next year, the company plans to start a Phase II trial evaluating ACH-3102 in combination with ACH-3422, a non-structural protein 5B (NS5B) polymerase inhibitor. ACH-3102 has Fast Track designation as part of an interferon-free regimen to treat chronic HCV infection. ...